Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment

Status Recruiting

Clinical Trial Summary

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled and randomly divided into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months. Basic characteristics will be evaluated at baseline by questionnaire. The hearing, liver and kidney functions, and neurotrophic factors will be examined at baseline, 4th month and 8th month.

Clinical Trial Description

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled. Inclusion criteria were 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB. Exclusion conditions were patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment, patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study. Participants will randomly divide into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months by a prospective, randomized, double-blind approach. Basic characteristics will be evaluated at baseline by questionnaire. The status of hearing, and CBC, GOT, GPT, BUN, Creatinine, NGF and BDNF expressions in blood will be examined at baseline, 4th month and 8th month. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03632512
Study type	Interventional
Source	Providence University, Taiwan
Contact	Yin-Ching Chan, PhD
Phone	886921376777
Email	ycchan@pu.edu.tw
Status	Recruiting
Phase	N/A
Start date	May 18, 2018
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05963542` - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia	N/A
Recruiting	`NCT04987502` - Virtual Reality and Subjective Tinnitus	N/A
Recruiting	`NCT04404439` - Treatment of Tinnitus With Migraine Medications	Phase 4
Recruiting	`NCT05533840` - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed	`NCT03552302` - Effects of Yoga Exercise on Participates With Tinnitus
Enrolling by invitation	`NCT02617953` - Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus	N/A
Completed	`NCT02269839` - A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus	N/A
Completed	`NCT02974543` - Somatosensory Stimulation to Alleviate Tinnitus	N/A
Withdrawn	`NCT01663467` - Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy	N/A
Completed	`NCT01929837` - Tinnitus rTMS 2013	N/A
Completed	`NCT01927991` - Internet-based Self-help for Tinnitus: The Role of Support	N/A
Completed	`NCT01857661` - The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial	N/A
Completed	`NCT01480193` - New Therapy for Patients With Severe Tinnitus	N/A
Terminated	`NCT01412918` - Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression	N/A
Completed	`NCT00371436` - Progressive Intervention Program for Tinnitus Management	N/A
Completed	`NCT00748475` - Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus	N/A
Completed	`NCT00733044` - Cost-effectiveness of Multidisciplinary Management of Tinnitus	N/A
Active, not recruiting	`NCT05518682` - Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus	N/A
Recruiting	`NCT05212298` - Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus	N/A
Completed	`NCT06025097` - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.